1887
  1. Home
  2. A-Z Publications
  3. Journal of Local and Global Health Science
  4. Volume 2013, Issue 1
  5. Article
Volume 2013, Issue 1
  • ISSN: 2223-0440
  • EISSN:

Abstract

Arsenic compounds have been known and used for centuries but their effects in living organisms still represent a large unknown. Arsenic compounds have paradoxical effects: they are threatening to human health, especially upon long-term exposure that can induce the development of cancer; however, they are used as drugs against cancer. This review focuses on the effects shown by clinically and environmentally relevant arsenic compounds in living organisms with a focus on the calcium–apoptosis link.

© 2013 Florea, Büsselberg, licensee Bloomsbury Qatar Foundation Journals.
Loading

Article metrics loading...

/content/journals/10.5339/jlghs.2013.1
2013-08-01
2024-04-20
Loading full text...

Full text loading...

/deliver/fulltext/jlghs/2013/1/jlghs.2013.1.html?itemId=/content/journals/10.5339/jlghs.2013.1&mimeType=html&fmt=ahah

References

  1. Florea AM, Büsselberg D. Occurrence, use and potential toxic effects of metals and metal compounds. Biometals. 2006; 19:4:419–427
     [Google Scholar]
  2. Florea AM, Büsselberg D. Differential modulation of the intracellular calcium concentration by anti-cancer drugs. Neurotoxicology. 2009 Sep; 30:5:803–810
     [Google Scholar]
  3. Ratnaike RN. Acute and chronic arsenic toxicity. Postgrad Med J. 2003; 79:933:391–396
     [Google Scholar]
  4. Florea AM. Toxicity of Alkylated Derivatives of Arsenic, Antimony and Tin: Cellular Uptake, Cytotoxicity, Genotoxic Effects, Perturbation of Ca2+ Homeostasis and Cell Death. Aachen: Shaker Verlag 2005;
     [Google Scholar]
  5. Vahidnia A, van der Voet GB, de Wolff FA. Arsenic neurotoxicity–a review. Hum Exp Toxicol. 2007 Oct; 26:10:823–832
     [Google Scholar]
  6. Kim KW, Chanpiwat P, Hanh HT, Phan K, Sthiannopkao S. Arsenic geochemistry of groundwater in Southeast Asia. Front Med. 2011 Dec; 5:4:420–433
     [Google Scholar]
  7. Abernathy CO, Liu YP, Longfellow D, Aposhian HV, Beck B, Fowler B, Goyer R, Menzer R, Rossman T, Thompson C, Waalkes M. Arsenic: health effects, mechanisms of actions, and research issues. Environ Health Perspect. 1999; 107:7:593–597
     [Google Scholar]
  8. Tchounwou PB, Wilson B, Ishaque A. Important considerations in the development of public health advisories for arsenic and arsenic-containing compounds in drinking water. Rev Environ Health. 1999; 14:4:211–229
     [Google Scholar]
  9. Sordo M, Herrera LA, Ostrosky-Wegman P, Rojas E. Cytotoxic and genotoxic effects of As, MMA, and DMA on leukocytes and stimulated human lymphocytes. Teratog Carcinog Mutagen. 2001; 21:4:249–260
     [Google Scholar]
  10. Jomova K, Jenisova Z, Feszterova M, Baros S, Liska J, Hudecova D, Rhodes CJ, Valko M. Arsenic: toxicity, oxidative stress and human disease. J Appl Toxicol. 2011 Mar;; 31:2:95–107. doi.10.1002/jat.1649
     [Google Scholar]
  11. Guha Mazumder D, Dasgupta UB. Chronic arsenic toxicity: studies in West Bengal, India. Kaohsiung J Med Sci. 2011 Sep; 27:9:360–370
     [Google Scholar]
  12. Huang CF, Chen YW, Yang CY, Tsai KS, Yang RS, Liu SH. Arsenic and diabetes: current perspectives. Kaohsiung J Med Sci. 2011 Sep; 27:9:402–410
     [Google Scholar]
  13. Bolt HM. Arsenic: an ancient toxicant of continuous public health impact, from Iceman Ötzi until now. Arch Toxicol. 2012 Jun; 86:6:825–830, doi: 10.1007/s00204-012-0866-7
     [Google Scholar]
  14. States JC, Barchowsky A, Cartwright IL, Reichard JF, Futscher BW, Lantz RC. Arsenic toxicology: translating between experimental models and human pathology. Environ Health Perspect. 2011 Oct; 119:10:1356–1363
     [Google Scholar]
  15. Lan CC, Yu HS, Ko YC. Chronic arsenic exposure and its adverse health effects in Taiwan: a paradigm for management of a global environmental problem. Kaohsiung J Med Sci. 2011 Sep; 27:9:411–416
     [Google Scholar]
  16. National Research Council. Arsenic in Drinking Water: 2001 Update. Washington, DC: National Academy Press 2001;
     [Google Scholar]
  17. Florea AM. The anticancer drug arsenic trioxide triggers calcium signaling and induces cell death by apoptosis in tumor and non-tumor cell models. Doctoral Thesis Presented to the Faculty of Medicine, University of Duisburg-Essen, Germany, January 2008
  18. Weider B, Fournier JH. Activation analyses of authenticated hairs of Napoleon Bonaparte confirm arsenic poisoning. Am J Forensic Med Pathol. 1999 Dec; 20:4:378–382
     [Google Scholar]
  19. Bergstrom SK, Gillan E, Quinn JJ, Altman AJ. Arsenic trioxide in the treatment of a patient with multiply recurrent, ATRA-resistant promyelocytic leukemia: a case report. J Pediatr Hematol Oncol. 1998; 20:6:545–547
     [Google Scholar]
  20. Shim MJ, Kim HJ, Yang SJ, Lee IS, Choi HI, Kim T. Arsenic trioxide induces apoptosis in chronic myelogenous leukemia K562 cells: possible involvement of p38 MAP kinase. J Biochem Mol Biol. 2002; 35:4:377–383
     [Google Scholar]
  21. Griffin RJ, Williams BW, Park HJ, Song CW. Preferential action of arsenic trioxide in solid-tumor microenvironment enhances radiation therapy. Int J Radiat Oncol Biol Phys. 2005; 61:5:1516–1522
     [Google Scholar]
  22. Breccia M, Lo-Coco F. Arsenic trioxide for management of acute promyelocytic leukemia: current evidence on its role in front-line therapy and recurrent disease. Expert Opin Pharmacother. 2012 May; 13:7:1031–1043
     [Google Scholar]
  23. Mathews V, Chandy M, Srivastava A. Arsenic trioxide in the management of acute promyelocytic leukaemia. Natl Med J India. 2001 Jul-Aug; 14:4:215–222
     [Google Scholar]
  24. Chen ZY, Liu TP, Yang Y. Manual of Clinical Drugs. Shanghai, China: Shanghai Science and Technology 1995;
     [Google Scholar]
  25. Zhang TC, Cao EH, Li JF, Ma W, Qin JF. Induction of apoptosis and inhibition of human gastric cancer MGC-803 cell growth by arsenic trioxide. Eur J Cancer. 1999; 35:8:1258–1263
     [Google Scholar]
  26. Du Y, Wang K, Fang H, Li J, Xiao D, Zheng P, Chen Y, Fan H, Pan X, Zhao C, Zhang Q, Imbeaud S, Graudens E, Eveno E, Auffray C, Chen S, Chen Z, Zhang J. Coordination of intrinsic, extrinsic, and endoplasmic reticulum-mediated apoptosis by imatinib mesylate combined with arsenic trioxide in chronic myeloid leukemia. Blood. 2006; 107:4:1582–1590
     [Google Scholar]
  27. Zhang P. The use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia. J Biol Regul Homeost Agents. 1999; 13:4:195–200
     [Google Scholar]
  28. Shen ZX, Chen GQ, Ni JH, Li XS, Xiong SM, Qiu QY, Zhu J, Tang W, Sun GL, Yang KQ, Chen Y, Zhou L, Fang ZW, Wang YT, Ma J, Zhang P, Zhang TD, Chen SJ, Chen Z, Wang ZY. Use of arsenic trioxide (As2O3) in the treatment of acute promyelocytic leukemia (APL): II. Clinical efficacy and pharmacokinetics in relapsed patients. Blood. 1997; 89:9:3354–3360
     [Google Scholar]
  29. Soignet SL, Frankel SR, Douer D, Tallman MS, Kantarjian H, Calleja E, Stone RM, Kalaycio M, Scheinberg DA, Steinherz P, Sievers EL, Coutré S, Dahlberg S, Ellison R, Warrell RP Jr. United States multicenter study of arsenic trioxide in relapsed acute promyelocytic leukemia. J Clin Oncol. 2001; 19:18:3852–3860
     [Google Scholar]
  30. Soignet SL, Maslak P, Wang ZG, Jhanwar S, Calleja E, Dardashti LJ, Corso D, DeBlasio A, Gabrilove J, Scheinberg DA, Pandolfi PP, Warrell RP Jr. Complete remission after treatment of acute promyelocytic leukemia with arsenic trioxide. N Engl J Med. 1998; 339:19:1341–1348
     [Google Scholar]
  31. Fenaux P, Chomienne C, Degos L. Treatment of acute promyelocytic leukaemia. Best Pract Res Clin Haematol. 2001; 14:1:153–174
     [Google Scholar]
  32. Zhu J, Chen Z, Lallemand-Breitenbach V, de The H. How acute promyelocytic leukaemia revived arsenic. Nat Rev Cancer. 2002; 2:9:705–713
     [Google Scholar]
  33. Kitchin KT. Recent advances in arsenic carcinogenesis: modes of action, animal model systems, and methylated arsenic metabolites. Toxicol Appl Pharmacol. 2001; 172:3:249–261
     [Google Scholar]
  34. Goddard MJ, Tanhehco JL, Dau PC. Chronic arsenic poisoning masquerading as Landry-Guillain-Barre syndrome. Electromyogr Clin Neurophysiol. 1992; 32:9:419–423
     [Google Scholar]
  35. Das NK, Sengupta SR. Arsenicosis: diagnosis and treatment. Indian J Dermatol Venereol Leprol. 2008 Nov-Dec; 74:6:571–581
     [Google Scholar]
  36. Tournel G, Houssaye C, Humbert L, Dhorne C, Gnemmi V, Bécart-Robert A, Nisse P, Hédouin V, Gosset D, Lhermitte M. Acute arsenic poisoning: clinical, toxicological, histopathological, and forensicfeatures. J Forensic Sci. 2011 Jan; 56 Suppl 1:S275–S279, doi: 10.1111/j.1556-4029.2010.01581.x
     [Google Scholar]
  37. Guo HR, Chiang HS, Hu H, Lipsitz SR, Monson RR. Arsenic in drinking water and incidence of urinary cancers. Epidemiology. 1997; 8:5:545–550
     [Google Scholar]
  38. Piao F, Ma N, Hiraku Y, Murata M, Oikawa S, Cheng F, Zhong L, Yamauchi T, Kawanishi S, Yokoyama K. Oxidative DNA damage in relation to neurotoxicity in the brain of mice exposed to arsenic at environmentally relevant levels. J Occup Health. 2005; 47:5:445–449
     [Google Scholar]
  39. Florea AM, Yamoah EN, Dopp E. Intracellular calcium disturbances induced by arsenic and its methylated derivatives in relation to genomic damage and apoptosis induction. Environ Health Perspect. 2005; 113:6:659–664
     [Google Scholar]
  40. Chiou HY, Huang WI, Su CL, Chang SF, Hsu YH, Chen CJ. Dose-response relationship between prevalence of cerebrovascular disease and ingested inorganic arsenic. Stroke. 1997; 28:9:1717–1723
     [Google Scholar]
  41. Morton WE, Caron GA. Encephalopathy: an uncommon manifestation of workplace arsenic poisoning? Am J Ind Med. 1989; 15:1:1–5
     [Google Scholar]
  42. Schenk VW, Stolk PJ. Psychosis following arsenic (possibly thallium) poisoning. A clinical-neuropathological report. Psychiatr Neurol Neurochir. 1967; 70:1:31–37
     [Google Scholar]
  43. Florea AM, Büsselberg D. Toxic effects of metals: use, benefits and toxic cellular effects. Materialwiss. u. Werkstofft. 2005;36:757–760
     [Google Scholar]
  44. Lee CH, Liao WT, Yu HS. Aberrant immune responses in arsenical skin cancers. Kaohsiung J Med Sci. 2011 Sep; 27:9:396–401
     [Google Scholar]
  45. Yang HC, Fu HL, Lin YF, Rosen BP. Pathways of arsenic uptake and efflux. Curr Top Membr. 2012; 69::325–358, doi: 10.1016/B978-0-12–39,4390-3.00012-4
     [Google Scholar]
  46. Qian Y, Castranova V, Shi X. New perspectives in arsenic-induced cell signal transduction. J Inorg Biochem. 2003; 96:2-3:271–278
     [Google Scholar]
  47. Yang C, Frenkel K. Arsenic-mediated cellular signal transduction, transcription factor activation, and aberrant gene expression: implications in carcinogenesis. J Environ Pathol Toxicol Oncol. 2002; 21:4:331–342
     [Google Scholar]
  48. Zhao CQ, Young MR, Diwan BA, Coogan TP, Waalkes MP. Association of arsenic-induced malignant transformation with DNA hypomethylation and aberrant gene expression. Proc Natl Acad Sci U S A. 1997; 94:20:10907–10912
     [Google Scholar]
  49. Liao WT, Lan CC, Lee CH, Yu HS. Concentration-dependent cellular responses of arsenic in keratinocytes. Kaohsiung J Med Sci. 2011 Sep; 27:9:390–395
     [Google Scholar]
  50. Reichard JF, Puga A. Effects of arsenic exposure on DNA methylation and epigenetic gene regulation. Epigenomics. 2010 Feb; 2:1:87–104
     [Google Scholar]
  51. Zhang Y, Wu JH, Han F, Huang JM, Shi SY, Gu RD, Chen XL, He B. Arsenic trioxide induced apoptosis in retinoblastoma cells by abnormal expression of microRNA-376a. Neoplasma. 2013 Feb; 60:3–253, doi: 10.4149/neo_2013_033
     [Google Scholar]
  52. Mattson MP, LaFerla FM, Chan SL, Leissring MA, Shepel PN, Geiger JD. Calcium signaling in the ER: its role in neuronal plasticity and neurodegenerative disorders. Trends Neurosci. 2000; 23:5:222–229
     [Google Scholar]
  53. Berridge MJ, Bootman MD, Roderick HL. Calcium signalling: dynamics, homeostasis and remodelling. Nat Rev Mol Cell Biol. 2003; 4:7:517–529
     [Google Scholar]
  54. Orrenius S, Zhivotovsky B, Nicotera P. Regulation of cell death: the calcium-apoptosis link. Nat Rev Mol Cell Biol. 2003; 4:7:552–565
     [Google Scholar]
  55. Florea AM, Splettstoesser F, Büsselberg D. Mechanisms of arsenic trioxide (As2O3) induced calcium signals and cellular death in two human SY-5Y Neuroblastoma and 293 embryonic kidney (HEK) cells. TAAP. 2007; 220:May:292–301
     [Google Scholar]
  56. Florea AM, Büsselberg D. Environmental and clinical relevant concentrations of arsenic trioxide (As2O3) induce calcium signals and and interfere with cell survival of human SY-5Y Neuroblastoma and 293 embryonic kidney (HEK) cells. Toxicol Lett. 2008 June; 179:1:34–42
     [Google Scholar]
  57. Ferguson C, Kern M, Audesirk G. Nanomolar concentrations of inorganic lead increase Ca2+ efflux and decrease intracellular free Ca2+ ion concentrations in cultured rat hippocampal neurons by a calmodulin-dependent mechanism. Neurotoxicology. 2000; 21:3:365–378
     [Google Scholar]
  58. Büsselberg D, Platt B, Michael D, Carpenter DO, Haas HL. Mammalian voltage-activated calcium channel currents are blocked by Pb2+, Zn2+, and Al3+ . J Neurophysiol. 1994; 71:4:1491–1497
     [Google Scholar]
  59. Büsselberg D. Calcium channels as target sites of heavy metals. Toxicol Lett. 1995; 82-83::255–261
     [Google Scholar]
  60. Orrenius S, Gogvadze V, Zhivotovsky B. Mitochondrial oxidative stress: implications for cell death. Annu Rev Pharmacol Toxicol. 2007; 47::143–183
     [Google Scholar]
  61. Zhivotovsky B, Orrenius S. Carcinogenesis and apoptosis: paradigms and paradoxes. Carcinogenesis. 2006; 27:10:1939–1945
     [Google Scholar]
  62. Fadeel B, Orrenius S. Apoptosis: a basic biological phenomenon with wide-ranging implications in human disease. J Intern Med. 2005; 258:6:479–517
     [Google Scholar]
  63. Green DR, Reed JC. Mitochondria and apoptosis. Science. 1998; 281:5381:1309–1312
     [Google Scholar]
  64. Robertson JD, Orrenius S. Role of mitochondria in toxic cell death. Toxicology. 2002; 181-182::491–496
     [Google Scholar]
  65. Orrenius S, Zhivotovsky B. The future of toxicology–does it matter how cells die? Chem Res Toxicol. 2006; 19:6:729–733
     [Google Scholar]
  66. Zimmermann KC, Pinkoski MJ. In the company of killers. Trends Mol Med. 2001; 7:5:195–197
     [Google Scholar]
  67. Zimmermann KC, Green DR. How cells die: apoptosis pathways. J Allergy Clin Immunol. 2001; 108:4 suppl:S99–103
     [Google Scholar]
  68. Zimmermann KC, Bonzon C, Green DR. The machinery of programmed cell death. Pharmacol Ther. 2001; 92:1:57–70
     [Google Scholar]
  69. Diaz Z, Colombo M, Mann KK, Su H, Smith KN, Bohle DS, Schipper HM, Miller WH Jr. Trolox selectively enhances arsenic-mediated oxidative stress and apoptosis in APL and other malignant cell lines. Blood. 2005; 105:3:1237–1245
     [Google Scholar]
  70. Zheng PZ, Wang KK, Zhang QY, Huang QH, Du YZ, Zhang QH, Xiao DK, Shen SH, Imbeaud S, Eveno E, Zhao CJ, Chen YL, Fan HY, Waxman S, Auffray C, Jin G, Chen SJ, Chen Z, Zhang J. Systems analysis of transcriptome and proteome in retinoic acid/arsenic trioxide-induced cell differentiation/apoptosis of promyelocytic leukemia. Proc Natl Acad Sci U S A. 2005; 102:21:7653–7658
     [Google Scholar]
  71. Kajiguchi T, Yamamoto K, Hossain K, Akhand AA, Nakashima I, Naoe T, Saito H, Emi N. Sustained activation of c-jun-terminal kinase (JNK) is closely related to arsenic trioxide-induced apoptosis in an acute myeloid leukemia (M2)-derived cell line, NKM-1. Leukemia. 2003; 17:11:2189–2195
     [Google Scholar]
  72. Miller WH Jr, Schipper HM, Lee JS, Singer J, Waxman S. Mechanisms of action of arsenic trioxide. Cancer Res. 2002; 62:14:3893–3903
     [Google Scholar]
  73. Zhou J, Meng R, Sui XH, Lu M, Wang DS, Yang BF. [Effects of protein tyrosine kinase, protein tyrosine phosphatase and protein kinase C on the apoptosis of arsenic trioxide treated NB4 cells and human cortex neurons]. Zhonghua Xue Ye Xue Za Zhi. 2004; 25:10:600–604
     [Google Scholar]
  74. Jarvis WD, Turner AJ, Povirk LF, Traylor RS, Grant S. Induction of apoptotic DNA fragmentation and cell death in HL-60 human promyelocytic leukemia cells by pharmacological inhibitors of protein kinase C. Cancer Res. 1994; 54:(7): 1707–1714
     [Google Scholar]
  75. Orrenius S. Mitochondrial regulation of apoptotic cell death. Toxicol Lett. 2004; 149:1-3:19–23
     [Google Scholar]
  76. Shen ZY, Shen WY, Chen MH, Shen J, Cai WJ, Zeng Y. Mitochondria, calcium and nitric oxide in the apoptotic pathway of esophageal carcinoma cells induced by As2O3 . Int J Mol Med. 2002; 9:4:385–390
     [Google Scholar]
  77. Zhang P, Wang S, Hu L, Qiu F, Yang H, Xiao Y, Li X, Han X, Zhou J, Liu P. [Seven years' summary report on the treatment of acute promyelocytic leukemia with arsenic trioxide-an analysis of 242 cases]. Zhonghua Xue Ye Xue Za Zhi. 2000; 21:2:67–70
     [Google Scholar]
  78. Davison K, Mann KK, Waxman S, Miller WH Jr. JNK activation is a mediator of arsenic trioxide-induced apoptosis in acute promyelocytic leukemia cells. Blood. 2004; 103:9:3496–3502
     [Google Scholar]
  79. Nutt LK, Gogvadze V, Uthaisang W, Mirnikjoo B, McConkey DJ, Orrenius S. Indirect effects of Bax and Bak initiate the mitochondrial alterations that lead to cytochrome c release during arsenic trioxide-induced apoptosis. Cancer Biol Ther. 2005; 4:4:459–467
     [Google Scholar]
  80. Bustamante J, Nutt L, Orrenius S, Gogvadze V. Arsenic stimulates release of cytochrome c from isolated mitochondria via induction of mitochondrial permeability transition. Toxicol Appl Pharmacol. 2005; 207:2 suppl:110–116
     [Google Scholar]
  81. Lorenzo HK, Susin SA, Penninger J, Kroemer G. Apoptosis inducing factor (AIF): a phylogenetically old, caspase-independent effector of cell death. Cell Death Differ. 1999; 6:6:516–524
     [Google Scholar]
  82. Ora I, Bondesson L, Jönsson C, Ljungberg J, Pörn-Ares I, Garwicz S, Pâhlman S. Arsenic trioxide inhibits neuroblastoma growth in vivo and promotes apoptotic cell death in vitro . Biochem.Biophys.Res.Commun. 2000; 277::179–185
     [Google Scholar]
  83. Wei YM, Ou YX, Bai H, Lu JH, Zheng RL. Down-regulation of four arsenic antagonists on apoptosis and telomerase activity induced by arsenic trioxide in three myelocytic leukemia cell lines. Acta Pharmacol Sin. 2001; 22:8:725–730
     [Google Scholar]
  84. Chen F, Lu Y, Zhang Z, Vallyathan V, Ding M, Castranova V, Shi X. Opposite effect of NF-kappa B and c-Jun N-terminal kinase on p53-independent GADD45 induction by arsenite. J Biol Chem. 2001a; 276:14:11414–11419
     [Google Scholar]
  85. Chen Z, Chen GQ, Shen ZX, Chen SJ, Wang ZY. Treatment of acute promyelocytic leukemia with arsenic compounds: in vitro and in vivo studies. Semin Hematol. 2001b; 38:1:26–36
     [Google Scholar]
  86. Verma A, Mohindru M, Deb DK, Sassano A, Kambhampati S, Ravandi F, Minucci S, Kalvakolanu DV, Platanias LC. Activation of Rac1 and the p38 mitogen-activated protein kinase pathway in response to arsenic trioxide. J Biol Chem. 2002; 277:47:44988–44995
     [Google Scholar]
  87. Haga N, Fujita N, Tsuruo T. Involvement of mitochondrial aggregation in arsenic trioxide (As2O3)-induced apoptosis in human glioblastoma cells. Cancer Sci. 2005; 96:11:825–833
     [Google Scholar]
  88. Chun YJ, Park IC, Park MJ, Woo SH, Hong SI, Chung HY, Kim TH, Lee YS, Rhee CH, Lee SJ. Enhancement of radiation response in human cervical cancer cells in vitro and in vivo by arsenic trioxide (As2O3). FEBS Lett. 2002; 519:1-3:195–200
     [Google Scholar]
  89. Lindskog M, Gleissman H, Ponthan F, Castro J, Kogner P, Johnsen JI. Neuroblastoma cell death in response to docosahexaenoic acid: sensitization to chemotherapy and arsenic-induced oxidative stress. Int J Cancer. 2006; 118:10:2584–2593
     [Google Scholar]
  90. Cheung WM, Chu PW, Kwong YL. Effects of arsenic trioxide on the cellular proliferation, apoptosis and differentiation of human neuroblastoma cells. Cancer Letters. 2007; 246:1-2:122–128
     [Google Scholar]
  91. Du YH, Ho PC. Arsenic compounds induce cytotoxicity and apoptosis in cisplatin-sensitive and -resistant gynecological cancer cell lines. Cancer Chemother Pharmacol. 2001; 47:6:481–490
     [Google Scholar]
  92. Kim S, Takeuchi A, Kawasumi Y, Endo Y, Lee H, Kim Y. A Guillain-Barré Syndrome-like Neuropathy Associated with Arsenic Exposure. J Occup Health. 2013; 31:54:(4):344–347
     [Google Scholar]
http://instance.metastore.ingenta.com/content/journals/10.5339/jlghs.2013.1
Loading
  • Article Type: Research Article

Most Cited Most Cited RSS feed

This is a required field
Please enter a valid email address
Approval was a Success
Invalid data
An Error Occurred
Approval was partially successful, following selected items could not be processed due to error